Innogenetics NV is a specialty diagnostics and therapeutic vaccine company that focuses in the field of infectious diseases, neurodegeneration, genetic testing, transplantation and oncology. The marketed diagnostic products of Innogenetics include INNO-LIA™, INNO-LiPA™ and INNOTEST™ useful as line immunoassays, line probe assays and enzyme immunoassays respectively for various antigens, antibodies and pathogens. Therapeutic vaccine portfolio includes - INNO101, a therapeutic vaccine in phase 2b clinical trails for treating hepatitis C, INNO102 in phase 1 trials for treating hepatitis B, ED009 a DNA vaccine in preclinical development for treating HPV and hepatitis C infections and ED001 a prophylactic hepatitis C vaccine. The product portfolio also includes LyphoDerm™ that is in phase 2 clinical trials for treating chronic leg ulcers and two biologics INNO 201, peptide for treating pulmonary edema and INNO 202, an antibody for septic shock.